Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
Clinical trial NCT02416232 · NO_LONGER_AVAILABLE
Trial details
- NCT number
- NCT02416232
- Sponsor
- GlaxoSmithKline
- Status
- NO_LONGER_AVAILABLE
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.